Ivermectin, Mebendazole and Fenbendazole in Cancer Research

For the past, uh, year and a half, I've been working with antiparasitics that are being repurposed for cancer.

This is ivermectin, uh, mebendazole, and fenbendazole.

And the reason is because there's a big body of research.

There are over four hundred published papers on ivermectin in cancer.

There are over two hundred and forty published papers on mebendazole in cancer.

In fact, Johns Hopkins quietly secured a patent in twenty twenty-one on mebendazole for treatment in cancer, specifically the most aggressive cancer, uh, which is glioblastoma, brain cancer, extremely aggressive cancer.

Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer.

There's colon cancer, uh, gastric cancer, and brain cancer, including children, children with, with brain cancers as well.

So this is not fringe. This is not, uh, something that is far out.

Uh, there's actually real science behind it, patents behind it.

Um, and when you search a lot of the AIs, uh, for example, Perplexity AI, and you ask, "What are the most promising repurposed drugs for terminally ill cancer patients today?"

It will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole.

Uh, there's other antiparasitics like hydroxychloroquine will be in the top ten.

You will have curcumin in the top ten. You will have EGCG, which is from a green tea extract, in the top ten.

Resveratrol in the top ten. Metformin, which is a diabetes drug, but also has anticancer activity, in the top ten as well.

And what I have found working with these antiparasitics is that, um, there is a benefit to patients in at least seventy-five percent of the cases